Judith Currier, MD, MSc
Judith S. Currier, MD, MSc, (Program Co-Director/Faculty Mentor) is Associate Director of the UCLA CARE Center, Professor of Medicine and Chief of the Infectious Diseases Division in the Department of Medicine of UCLA DGSOM. She is Co-Director of the AIDS Clinical Trial Group (ACTG) network, having contributed since 1990 to the development, implementation and analysis of clinical research studies in the ACTG. Dr. Currier collaborated in the formation of the Fiocruz ACTG site in Rio de Janeiro, and continues to serve as a mentor to the site’s staff and investigators. She was co-Chair of two international ACTG trials, A5208, evaluating the impact of prior exposure to single dose nevirapine on response to ARV therapy in women, and A5190, evaluating the outcomes of children exposed in utero to antiretroviral therapy during clinical trials. Dr. Currier holds a K24 grant for mentoring Faculty and Fellows at UCLA and Fiocruz. Her research focuses on metabolic outcomes of antiretroviral therapy, including gender-specific responses to treatment, and optimization of antiretroviral therapy, including studies of ARV regimens in international settings.
Antiretroviral therapeutics
Metabolic complications of antiretroviral therapy
Clinical trials
Currier JS, Kendall M, Henry K, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007 May 31; 21(9):1137-45.
Currier JS, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K; GRACE (Gender, Race And Clinical Experience) Study Group. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010 Sep 21;153(6):349-57.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of Microbial Translocation and Macrophage Activation are Associated with Progression of Subclinical Atherosclerosis in HIV-1 Infection. J Infect Dis. 2012 Nov 15;206(10):1558-67.
Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15;59(6):888-96.
Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier JS. Cardiovascular Disease Risk Factors in HIV-Infected Women After Initiation of Lopinavir/Ritonavir- and Nevirapine-Based Antiretroviral Therapy in Sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):155-63.
Applications for the 2024-25 Fellowship class are now being accepted. The priority application deadline for the 2024-25 Fellowship class is February 16, 2024.